Qiagen N.V. Class Action Lawsuit - QGEN

The filed complaint alleges that Qiagen N.V. made materially false and/or misleading statements and/or failed to disclose that: During the previous earnings call on February 5, 2026, CEO Thierry Bernard was confident: “You will see QuantiFERON picking up in Q2 … accelerating to achieve … between 6% and 7% growth” in 2026. He noted Qiagen’s projections remained “perfectly aligned with the target that we gave during our Capital Market Day in June 2024.” On April 28, 2026, Qiagen walked back on these claims and CFO Roland Sackers revealed the disappointing guidance: sales were now projected to “continue at a largely unchanged level from the second quarter of 2025,” and investors would have to wait for QuantiFERON to “return to a more normalized growth rate in 2027.”

In order to be eligible to join the QGEN class action lawsuit, you must have incurred a loss on shares of Qiagen N.V. purchased during the class period listed above.